📰🧠🔬 ALZHEIMER’S DISEASE STUDY HIGHLIGHTS – Serum Homocysteine as a Potential Dynamic Biomarker for Staging and Monitoring Progression in Alzheimer’s Disease by Wu C, et al.

This study investigates whether serum homocysteine (Hcy), a blood biomarker, can be used to assess severity and monitor progression in Alzheimer’s disease (AD), and whether it changes with treatment.

Key Findings:
• AD patients had higher Hcy levels than healthy controls.
• Hcy increased with disease severity (mild → severe).
• Strong negative correlation with cognition (higher Hcy = worse MMSE/MoCA scores, r = −0.76).
• Hcy could distinguish AD severity (AUC = 0.87; cutoff ≈17.5 μmol/L).
• After 6 months of B-vitamin treatment, Hcy decreased and cognition improved.

Key takeaways:
The preliminary evidence shows that Hcy levels are positively correlated with the severity of AD and closely associated with cognitive decline. The reduction in Hcy levels following intervention, accompanied by cognitive improvement, suggests its potential value for monitoring disease progression and treatment response.

📄 Access the full article at: Wu C, Wu C, Yin X, Zhong C. Serum Homocysteine as a Potential Dynamic Biomarker for Staging and Monitoring Progression in Alzheimer’s Disease. Neuropsychiatr Dis Treat. 2026;22:553269 https://www.dovepress.com/serum-homocysteine-as-a-potential-dynamic-biomarker-for-staging-and-mo-peer-reviewed-fulltext-article-NDT. This is an open-access article under a CC BY-NC 4.0 licence.